Predict your next investment

Slater Technology Fund company logo
Venture Capital
FINANCIAL | Investment Firms & Funds
slaterfund.com

See what CB Insights has to offer

Investments

72

Portfolio Exits

5

About Slater Technology Fund

The Slater Technology Fund is an evergreen not-for-profit seed fund dedicated to supporting new venture development in Rhode Island.

Slater Technology Fund Headquarter Location

3 Davol Square

Providence, Rhode Island, 2903,

United States

401-831-6633

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Slater Technology Fund Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Slater Technology Fund Rank

Latest Slater Technology Fund News

Slater Technology Fund-backed company to be acquired by Novartis

Dec 18, 2020

Slater Technology Fund-backed company to be acquired by Novartis By A SLATER TECHNOLOGY FUND-backed company, Cadent Therapeutics, has entered into an agreemnt to be acquired by Novartis in a deal worth up to $770 million. PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to $770 million, Slater Technology Fund announced Friday. The company was formed through a merger with the Slater Technology Fund-backed company Mnemosyne Pharmaceuticals. Mnemosyne developed a drug-discovery program targeting the creation of novel therapeutics to treat cognitive dysfunction and a broad range of central nervous system disorders. Slater, an evergreen not-for-profit seed fund dedicated to supporting new venture development in Rhode Island, invested $1.5 million in Mnemosyne, which became an ownership stake in Cadent. Slater noted that former Mnemosyne co-founder Frank Menniti has gone on to start MindImmunue Therapeutics, another Slater-backed company. Mnemosyne moved to Cambridge in 2015 as Luc Therapeutics after finishing an $11.5 million Series A financing round, and merged with Ataxion in 2017 to become Cadent. - Advertisement - “It is incredibly gratifying to see seed investments blossom in so many ways. Congratulations to [CEO of Cadent Therapeutics] Jodie Morrison and her team on creating such a great outcome for all, and to the Mnemosyne founders, who teamed with Richard Horan and Slater a decade ago,” said Thorne Sparkman, managing director of Slater. “This kind of success quite literally fuels the impact that entrepreneurs like the Mnemosyne founders can make by augmenting Slater’s evergreen investment in the next generation of ventures. We cannot wait to pay it forward.” Slater said the deal marked the fourth positive liquidity event for the fund in the past two years. Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber. TAGS

Slater Technology Fund Investments

72 Investments

Slater Technology Fund has made 72 investments. Their latest investment was in Datarista as part of their Series A on March 3, 2021.

CBI Logo

Slater Technology Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/5/2021

Series A

Datarista

$0.75M

No

1

10/15/2020

Seed VC - V

Datarista

$0.06M

No

1

11/1/2019

Unattributed VC

MindImmune Therapeutics

$0.75M

Yes

1

8/2/2019

Series A - V

Subscribe to see more

$99M

Subscribe to see more

10

3/13/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/5/2021

10/15/2020

11/1/2019

8/2/2019

3/13/2019

Round

Series A

Seed VC - V

Unattributed VC

Series A - V

Series A

Company

Datarista

Datarista

MindImmune Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$0.75M

$0.06M

$0.75M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Slater Technology Fund Portfolio Exits

5 Portfolio Exits

Slater Technology Fund has 5 portfolio exits. Their latest portfolio exit was IlluminOss Medical on May 01, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/1/2020

Acq - Fin

5

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

5/1/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

10

10

Slater Technology Fund Team

3 Team Members

Slater Technology Fund has 3 team members, including current Managing Director, Thorne Sparkman.

Name

Work History

Title

Status

Thorne Sparkman

Managing Director

Current

Richard G. Horan

M2S, Sachem Ventures, Immunicon, Johnston Associates, and Bank of America

Managing Director

Former

Ronald Unterman

Managing Director

Former

Name

Thorne Sparkman

Richard G. Horan

Ronald Unterman

Work History

M2S, Sachem Ventures, Immunicon, Johnston Associates, and Bank of America

Title

Managing Director

Managing Director

Managing Director

Status

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.